A novel bispecific antibody fusion protein co-targeting EGFR and CD47 with enhanced therapeutic index

Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses

(2017) Boning Liu et al.   mAbs

Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies

(2017) Elie Dheilly et al.   MOLECULAR THERAPY

Targeting CD47: the achievements and concerns of current studies on cancer immunotherapy

(2017) Yuting Huang et al.   Journal of Thoracic Disease

Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma

(2015) Zhenyu Xiao et al.   CANCER LETTERS

A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells

(2015) Emily C Piccione et al.   mAbs

Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency

(2015) Yun Yang et al.   mAbs

Macrophages are critical effectors of antibody therapies for cancer

(2015) Kipp Weiskopf et al.   mAbs

CD47 blockade triggers T cell–mediated destruction of immunogenic tumors

(2015) Xiaojuan Liu et al.   NATURE MEDICINE

Signal-regulatory proteinαfrom the NOD mouse binds human CD47 with an exceptionally high affinity - implications for engraftment of human cells

(2014) Lai Shan Kwong et al.   IMMUNOLOGY

Antibodies directed against receptor tyrosine kinases

(2014) Bénédicte FAUVEL et al.   mAbs

A CD47-blocking TRAIL fusion protein with dual pro-phagocytic and pro-apoptotic anticancer activity

(2013) Valerie R. Wiersma et al.   BRITISH JOURNAL OF HAEMATOLOGY

Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity

(2013) Whitney Shatz et al.   mAbs

Engineered SIRP  Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies

(2013) K. Weiskopf et al.   SCIENCE

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors

(2012) S. B. Willingham et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma

(2010) Mark P. Chao et al.   CELL

Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

(2010) J. R. Junutula et al.   CLINICAL CANCER RESEARCH

Functions and molecular mechanisms of the CD47–SIRPα signalling pathway

(2009) Takashi Matozaki et al.   TRENDS IN CELL BIOLOGY

Effector mechanisms of therapeutic antibodies against ErbB receptors

(2008) Matthias Peipp et al.   CURRENT OPINION IN IMMUNOLOGY